Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
18
-
Total 13F principal, excl. options
-
273,236,000
-
Principal change
-
+23,853,000
-
Total reported value, excl. options
-
$226,785,000
-
Value change
-
+$15,533,536
-
Number of buys
-
6
-
Number of sells
-
-9
-
Price
-
$0.8156
Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2022
21 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2022.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 18 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $273,236,000 of principal
.
Largest 10 bondholders include Kohlberg Kravis Roberts & Co. L.P. ($52,083,000 of principal), FRANKLIN RESOURCES INC ($48,000,000 of principal), COWEN AND COMPANY, LLC ($36,800,000 of principal), LAZARD ASSET MANAGEMENT LLC ($27,270,000 of principal), AVIVA PLC ($22,325,000 of principal), UBS OCONNOR LLC ($20,000,000 of principal), ZAZOVE ASSOCIATES LLC ($15,058,000 of principal), Antara Capital LP ($15,000,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($13,500,000 of principal), and AMUNDI ($6,232,000 of principal).
This table shows the top 18 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.